Similar observations have been reported by recent preclinical studies in which PARPi treatment alone led to an activation of PI3K/AKT signaling, and thus was insufficient to abrogate the growth of prostate and breast tumors.30, 38 Together, these results indicate that activation of pro-survival PI3K/AKT signaling may compromise the efficacy of PARPi, raising the caution of PARP inhibitor monotherapy in the treatments of endometrioid endometrial cancer. Here, AKT1 is linked to breast neoplasm.